A molecular signature in blood identifies early Parkinson’s disease

[1] Hughes AJ(1992)Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases J Neurol Neurosurg Psychiatry 55 181-184

[2] Daniel SE(1997)Evaluation of the Short Parkinson’s Evaluation Scale: a new friendly scale for the evaluation of Parkinson’s disease in clinical drug trials Clin Neuropharmacol 20 322-337

[3] Kilford L(2004)A short scale for the assessment of motor impairments and disabilities in Parkinson’s disease: the SPES/SCOPA J Neurol Neurosurg Psychiatry 75 388-395

[4] Lees AJ(1967)Parkinsonism: onset, progression and mortality Neurology 17 427-442

[5] Rabey JM(1992)What features improve the accuracy of clinical diagnosis in Parkinson’s disease: a clinicopathologic study Neurology 42 1142-1146

[6] Bass H(2003)Routine MRI for the differential diagnosis of Parkinson’s disease, MSA, PSP, and CBD J Neural Transm 110 151-169

[7] Bonuccelli U(1995)Differentiation of multiple system atrophy from idiopathic Parkinson’s disease using proton magnetic resonance spectroscopy Ann Neurol 37 204-210

[8] Brooks D(1999)Phosphorus magnetic resonance spectroscopy in multiple system atrophy and Parkinson’s disease Mov Disord 14 430-435

[9] Klotz P(2000)The evolution of diagnosis in early Parkinson disease. Parkinson Study Group Arch Neurol 57 369-372

[10] Korczyn AD(2004)Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes J Neural Transm 111 1543-1573

[1] Hughes AJ(1992)Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases J Neurol Neurosurg Psychiatry 55 181-184

[2] Daniel SE(1997)Evaluation of the Short Parkinson’s Evaluation Scale: a new friendly scale for the evaluation of Parkinson’s disease in clinical drug trials Clin Neuropharmacol 20 322-337

[3] Kilford L(2004)A short scale for the assessment of motor impairments and disabilities in Parkinson’s disease: the SPES/SCOPA J Neurol Neurosurg Psychiatry 75 388-395

[4] Lees AJ(1967)Parkinsonism: onset, progression and mortality Neurology 17 427-442

[5] Rabey JM(1992)What features improve the accuracy of clinical diagnosis in Parkinson’s disease: a clinicopathologic study Neurology 42 1142-1146

[6] Bass H(2003)Routine MRI for the differential diagnosis of Parkinson’s disease, MSA, PSP, and CBD J Neural Transm 110 151-169

[7] Bonuccelli U(1995)Differentiation of multiple system atrophy from idiopathic Parkinson’s disease using proton magnetic resonance spectroscopy Ann Neurol 37 204-210

[8] Brooks D(1999)Phosphorus magnetic resonance spectroscopy in multiple system atrophy and Parkinson’s disease Mov Disord 14 430-435

[9] Klotz P(2000)The evolution of diagnosis in early Parkinson disease. Parkinson Study Group Arch Neurol 57 369-372

[10] Korczyn AD(2004)Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes J Neural Transm 111 1543-1573